Los Angeles Capital Management LLC lessened its position in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) by 11.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 51,531 shares of the company's stock after selling 6,740 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.12% of Meridian Bioscience worth $1,338,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in VIVO. Advisor Group Holdings Inc. grew its position in shares of Meridian Bioscience by 6.1% during the 1st quarter. Advisor Group Holdings Inc. now owns 16,453 shares of the company's stock worth $464,000 after buying an additional 940 shares during the period. Teton Advisors Inc. grew its position in shares of Meridian Bioscience by 6.4% during the 4th quarter. Teton Advisors Inc. now owns 25,000 shares of the company's stock worth $510,000 after buying an additional 1,500 shares during the period. Horan Securities Inc. acquired a new stake in shares of Meridian Bioscience during the 4th quarter worth approximately $33,000. Prospera Financial Services Inc acquired a new stake in shares of Meridian Bioscience during the 1st quarter worth approximately $42,000. Finally, Rhumbline Advisers grew its position in shares of Meridian Bioscience by 1.4% during the 4th quarter. Rhumbline Advisers now owns 126,390 shares of the company's stock worth $2,578,000 after buying an additional 1,778 shares during the period. Institutional investors and hedge funds own 94.72% of the company's stock.
Get
Meridian Bioscience alerts:
Meridian Bioscience Stock Performance
NASDAQ VIVO opened at $32.75 on Thursday. The company has a fifty day simple moving average of $30.77 and a 200 day simple moving average of $27.32. Meridian Bioscience, Inc. has a 12-month low of $17.20 and a 12-month high of $34.38. The company has a current ratio of 3.85, a quick ratio of 2.60 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.43 billion, a P/E ratio of 33.08 and a beta of 0.28.
Insider Activity at Meridian Bioscience
In related news, CEO John P. Kenny sold 13,559 shares of Meridian Bioscience stock in a transaction on Friday, June 24th. The shares were sold at an average price of $30.00, for a total value of $406,770.00. Following the completion of the sale, the chief executive officer now owns 265,131 shares of the company's stock, valued at approximately $7,953,930. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Meridian Bioscience news, CEO John P. Kenny sold 13,559 shares of the firm's stock in a transaction on Friday, June 24th. The stock was sold at an average price of $30.00, for a total transaction of $406,770.00. Following the transaction, the chief executive officer now directly owns 265,131 shares in the company, valued at approximately $7,953,930. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John P. Kenny sold 44,651 shares of the firm's stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $29.72, for a total value of $1,327,027.72. Following the transaction, the chief executive officer now owns 265,131 shares in the company, valued at $7,879,693.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 119,647 shares of company stock valued at $3,600,868. 2.30% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
VIVO has been the subject of several recent analyst reports. StockNews.com downgraded shares of Meridian Bioscience from a "buy" rating to a "hold" rating in a research report on Tuesday. William Blair downgraded shares of Meridian Bioscience from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 7th. Finally, HC Wainwright downgraded shares of Meridian Bioscience from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $30.00 to $34.00 in a research report on Friday, July 8th.
Meridian Bioscience Profile
(Get Rating)
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.
Further Reading
- Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating).
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
